PuSH - Publication Server of Helmholtz Zentrum München: A common human MLKL polymorphism confers resistance to negative regulation by phosphorylation.

Information

Clues to quality of journals

Open Access Policy of Helmholtz Association 2016

CC Licencences

Publication Metrics

Navigation

Home

Deutsch

EVA: Electronic Publishing

New EVA Application

Research

Advanced Search

Browse by ...

... HMGU-Authors/Consortia

... Organizational Structure

... Journal

... Publication Type

... Research Data

... Arbeitsgruppen

... Publication Year

Publication overview

Statistics

Statistics (last 5 years)

OA Publications

Publish

Submit Publication

Import publication from...

...EVA

Report missing publication

Highlights

Support & Contact

Contact persons

Help

Data protection

Helmholtz Open Science

JANE Journal Estimator

SHERPA/RoMEO

DOAJ

Export:

Text

Endnote (RIS) BIB

BibTeX

Garnish, S.E.* ; Martin, K.R.* ; Kauppi, M.* ; Jackson, V.E.* ; Ambrose, R.* ; Eng, V.V.* ; Chiou, S.* ; Meng, Y.* ; Frank, D.* ; Tovey Crutchfield, E.C.* ; Patel, K.M.* ; Jacobsen, A.V.* ; Atkin-Smith, G.K.* ; Di Rago, L.* ; Doerflinger, M.* ; Horne, C.R.* ; Hall, C.* ; Young, S.N.* ; Cook, M.* ; Athanasopoulos, V.* ; Vinuesa, C.G.* ; Lawlor, K.E.* ; Wicks, I.P.* ; Ebert, G. ; Ng, A.P.* ; Slade, C.A.* ; Pearson, J.S.* ; Samson, A.L.* ; Silke, J.* ; Murphy, J.M.* ; Hildebrand, J.M.*

A common human MLKL polymorphism confers resistance to negative regulation by phosphorylation.

Nat. Commun. 14:6046 (2023)

Publ. Version/Full Text

DOI

PMC

	Open Access Gold

Abstract
Metrics
Extra information

Across the globe, 2-3% of humans carry the p.Ser132Pro single nucleotide polymorphism in MLKL, the terminal effector protein of the inflammatory form of programmed cell death, necroptosis. Here we show that this substitution confers a gain in necroptotic function in human cells, with more rapid accumulation of activated MLKLS132P in biological membranes and MLKLS132P overriding pharmacological and endogenous inhibition of MLKL. In mouse cells, the equivalent Mlkl S131P mutation confers a gene dosage dependent reduction in sensitivity to TNF-induced necroptosis in both hematopoietic and non-hematopoietic cells, but enhanced sensitivity to IFN-β induced death in non-hematopoietic cells. In vivo, Mlkl S131P homozygosity reduces the capacity to clear Salmonella from major organs and retards recovery of hematopoietic stem cells. Thus, by dysregulating necroptosis, the S131P substitution impairs the return to homeostasis after systemic challenge. Present day carriers of the MLKL S132P polymorphism may be the key to understanding how MLKL and necroptosis modulate the progression of complex polygenic human disease.

Impact Factor

Scopus SNIP

Altmetric

16.600

0.000